{"pmid": "11896112", "sentences": {"sent_1": {"Section": "", "text": "PATIENTS AND METHODS : Forty - nine children were enrolled onto this phase I trial ( 24 with acute nonlymphoblastic leukemia [ ANLL ] and 25 with acute lymphoblastic leukemia [ ALL ] ) .", "entities": {"entity_1": {"text": "children", "class": "Participant", "negation": 0, "UMLS": "", "index": 1, "start": 7}, "entity_2": {"text": "acute nonlymphoblastic leukemia [ ANLL ]", "class": "Participant", "negation": 0, "UMLS": "C0023467:acute nonlymphoblastic leukemia,C0023467:anll,", "index": 2, "start": 18}, "entity_3": {"text": "acute lymphoblastic leukemia [ ALL ]", "class": "Participant", "negation": 0, "UMLS": "C0023449:acute lymphoblastic leukemia,", "index": 3, "start": 27}}, "relations": {}}, "sent_2": {"Section": "", "text": "TPT dosage was escalated from 2.0 to 5.2 mg / m ( 2 ) / d for 5 days and 2.4 mg / m ( 2 ) / d from 7 days to the same dose for 9 and 12 days in cohorts of three to six patients when no DLT was identified .", "entities": {"entity_4": {"text": "TPT dosage", "class": "Intervention", "negation": 0, "UMLS": "", "index": 1, "start": 0}, "attribute_1": {"text": "2.0 to 5.2 mg / m ( 2 ) / d", "class": "measure", "negation": 0, "UMLS": "", "index": 2, "start": 5}, "attribute_2": {"text": "2.4 mg / m", "class": "measure", "negation": 0, "UMLS": "", "index": 3, "start": 20}, "entity_5": {"text": "DLT", "class": "Intervention", "negation": 0, "UMLS": "", "index": 4, "start": 50}}, "relations": {}}, "sent_3": {"Section": "", "text": "TPT pharmacokinetics were studied in 33 children once or twice ( first and last doses in patients who received TPT for > 7 days ) .", "entities": {"entity_6": {"text": "TPT pharmacokinetics", "class": "Outcome", "negation": 0, "UMLS": "C0031327:pharmacokinetics,", "index": 1, "start": 0}, "entity_7": {"text": "TPT", "class": "Intervention", "negation": 0, "UMLS": "", "index": 2, "start": 19}}, "relations": {}}}}